Recent studies have indicated that upregulated glycolysis, achieved by either a high-glucose diet or genetic or pharmacological activation of glycolytic enzymes, might mitigate the disease phenotype in animal models or patients with NDDs, including ALS, Parkinson’s disease, and Huntington’s disease86–88. This evidence concerns the gene HK1 and Parkinson disease.